Top

Osteoporosis International

Published in:

01-11-2012 | Short Communication

Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws

Authors: Y.-D. Kwon, D.-W. Lee, B.-J. Choi, J.-W. Lee, D.-Y. Kim

Published in: Osteoporosis International | Issue 11/2012

Abstract

Summary

To review the effect of teriparatide as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws (BRONJ), we describe a series of cases of teriparatide therapy for the treatment of BRONJ and serial changes of serum osteoclacin (s-OC) and serum C-terminal telopeptide cross-link of type I collagen (s-CTX).

Introduction

Management of BRONJ is quite challenging and the currently recommended modalities for BRONJ are still suboptimal. For the improvement of bony remodeling, some clinicians advocated bisphosphonate holiday although validity of this drug holiday has been debated so far. Recently, the use of teriparatide was introduced in several cases, but the number of the publication is limited and mostly anecdotal so far.

Method

Bisphosphonate was suspended and teriparatide was given to six patients diagnosed with BRONJ by single bone specialist. Medical record review and interviews were carried out. S-CTX and s-OC were measured at the baseline, 2 months and 3 months later teriparatide therapy. The outcome of the treatment and the change of biochemical markers were compared.

Result

In all six patients, s-OC values were significantly elevated within 2 months after teriparatide treatment and the BRONJ lesions were healed. S-CTX values were also elevated in four patients, whereas those of the rest two patients stayed within minimal change. The change was marginally significant at 3 months.

Conclusion

In terms of the multifactorial etiology of BRONJ, bone formation suppression was noticed in the patients. Based upon this finding, the short-term use of teriparatide might be beneficial to the resolution of BRONJ lesions by improving suppressed bone remodeling.

Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH (2010) Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck 33(9):1366–1371CrossRefPubMed

Kyrgidis A, Antoniades K (2010) Could teriparatide be the treatment for osteonecrosis of the jaws? Head Neck 33(9):1382–1383CrossRefPubMed

Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65:573–580CrossRefPubMed

Cheung A, Seeman E (2010) Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473–2474CrossRefPubMed

Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA (2008) Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am 90(Suppl 1):120–127CrossRefPubMed

Miller SC, Hunziker J, Mecham M, Wronski TJ (1997) Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats. J Dent Res 76:1471–1476CrossRefPubMed

Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941CrossRefPubMed

Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M (2003) New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008–2015CrossRefPubMed

Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surgery 67:85–95CrossRef

10.

Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporosis Int 19:1613–1620CrossRef

11.

Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938CrossRefPubMed

12.

Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRefPubMed

13.

Kwon YD, Ohe JY, Kim DY, Chung DJ, Park YD (2011) Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res 22:100–105CrossRefPubMed

14.

Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporosis Int 20:2095–2104CrossRef

15.

Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefPubMed

16.

Khosla S, Burr D, Cauley J et al (2008) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66:1320–1321, author reply 1321-1322CrossRefPubMed

17.

Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C (2009) Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:2644–2648CrossRefPubMed

18.

Pazianas M, Blumentals WA, Miller PD (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporosis Int 19:773–779CrossRef

19.

Lateef M, Baig M, Azhar A (2010) Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females. Osteoporosis Int 21:751–755CrossRef

20.

Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC (2000) Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 11:295–303CrossRefPubMed

Title: Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws
Authors: Y.-D. Kwon
D.-W. Lee
B.-J. Choi
J.-W. Lee
D.-Y. Kim
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 11/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1882-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws

Abstract

Summary

Introduction

Method

Result

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2012

Autosomal recessive osteopetrosis: report of 41 novel mutations in the TCIRG1 gene and diagnostic implications

Erratum to: Autosomal recessive osteopetrosis: report of 41 novel mutations in the TCIRG1 gene and diagnostic implications

Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?

Calcium supplementation, renin, and vascular risk

Reply to Subramanian and Quek: Teriparatide’s role in the management of bisphosphonate-associated osteonecrosis of the jaw

Expression of endothelial nitric oxide synthase protein is not necessary for mechanical strain-induced nitric oxide production by cultured osteoblasts